A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-27

Study Completion Date

2018-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical study of the use of glargine insulin in 2 subjects with type two diabetes in China was carried out. The two kinds of injection methods were evaluated as subcutaneous injection of insulin glargine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing the Effects of Insulin Glargine on Blood Glucose Between Needle-free Jet Injection and Insulin Pen

NCT04074603

Type 2 Diabetes

COMPLETED NA

Comparison of Safety and Efficacy of QS-M Needle- Free Injector and Insulin Pen in Controlling T2DM Patient's Glucose

NCT03243903

Diabetes

COMPLETED NA

Evaluation of Efficacy and Safety of Insulin Glargine Injected by Needle-free Jet Syringe

NCT04093284

Diabetes Mellitus, Type 2

UNKNOWN NA

Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM

NCT04682795

T2DM (Type 2 Diabetes Mellitus) Needle-free Injector Time in Range

UNKNOWN NA

Pharmacokinetic and Pharmacodynamic Profile of Insulin Lispro Using Needle-Free Jet Injection Technology

NCT02443714

Healthy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

QS-M Needle Free Injector group

To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.

Group Type EXPERIMENTAL

QS-M Needle Free Injector

Intervention Type DEVICE

The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection

Glargine pen group

To observe the amount of insulin used by the Glargine pen group under good blood glucose control.

Group Type ACTIVE_COMPARATOR

Glargine pen

Intervention Type DEVICE

The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QS-M Needle Free Injector

The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection

Intervention Type DEVICE

Glargine pen

The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. male or female aged 18-70 years of age, women of childbearing age need to take adequate contraceptive measures to minimize the risk of pregnancy;
2. the standard of diagnosis of type 2 diabetes and the course of the disease is more than half a year;
3. 18 Kg/m2 = BMI = 30Kg/m2;
4. received daily injections of insulin glargine and also take one to three kinds of oral medicine (not including secretagogues) patients, daily insulin glargine total dose more than 12IU but \<50IU, the use of insulin glargine than in January;
5. the blood glucose in the fasting vein was in 5.0-9.0mmol/L;
6. the letter of informed consent has been read and signed.

Exclusion Criteria

1. there is conflict of interest with this research.
2. blood glucose control is not good enough to participate in this study, such as repeated hypoglycemia, diabetic ketoacidosis or hyperosmolar coma.
3. serious diabetic complications such as diabetic foot, diabetic nephropathy and so on;
4. severe cardiovascular events occurred in the last 6 months.
5. the application of hormone or immunosuppressant, or low immunity defect;
6. the use of non steroidal anti-inflammatory drugs;
7. the use of sulfonylureas and insulin secreting agents;
8. a person with a history of cancer;
9. a history of unstable or rapid progressive renal disease;
10. an unstable history of major mental illness;
11. the history of hemoglobin (such as sickle red cell anemia, thalassemia, iron granulocytic anemia);
12. women who are pregnant or are breastfeeding;
13. in the near future there is a clear infection, such as urinary tract infection and pneumonia;
14. recent important visceral hemorrhage, such as gastric hemorrhage and cerebral hemorrhage, etc.
15. skin diseases such as exfoliative dermatitis, pustular sore and infection of pyogenic bacteria;
16. the history of acute pancreatitis or pancreatectomy;
17. the researchers believe that it may lead to any situation in which the subject is unable to complete the study or may cause significant risk to the subject.
18. the results of the laboratory examination are as follows: A. obvious abnormal liver function or in the active phase of the disease (AST\> 3 times the upper limit of normal ALT\> or 3 times the upper limit of normal); The creatinine clearance rate of B. was \<60ml/min; C. anaemia caused by any cause of the disease; The results of pregnancy test in women of childbearing age of D. were positive.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No